About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, November 8th, 2013

The QualityStocks
Daily Stock List


NaturalNano, Inc. (NNAN)

Stocktwiter, PennyStocks24, The Stock Psycho, Penny Stock Rumble, Darth Trader, and InvestorTrendz reported earlier on NaturalNano, Inc. (NNAN), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2004, Rochester, New York-based NaturalNano, Inc. is a nanomaterials company. The Company is developing proprietary technologies and processes to provide novel properties for a broad spectrum of applications. NaturalNano develops distinctive and proprietary processes for refining naturally occurring nanotubes and other nanomaterials that add competitive properties to an array of applications. NaturalNano’s shares trade on the OTC Markets’ OTCQB

NaturalNano has 20 licensed, issued, or pending patents and the expertise for extracting and separating clay Halloysite Nanotubes (HNTTM). Halloysite nanotubes are unique and versatile nanomaterials. They are formed by surface weathering of aluminosilicate minerals and they consist of aluminum, silicon, hydrogen, and oxygen.

Halloysite nanotubes are ultra-tiny hollow tubes with diameters usually smaller than 100 nanometers (100 billionths of a meter), with lengths generally ranging from approximately 500 nanometers to more than 1.2 microns (millionths of a meter). Filled nanotubes allow for use in cosmetics, odor masking, agriculture, medicine, and several other applications requiring extended release.

NaturalNano has their PleximerTM product. This is a turnkey HNT polymer concentrate, in pellet form, that can be added directly into a polymer extruder. Pleximer is formulated using the Company’s patent-pending process that offers premier performance properties. Pleximer contains Halloysite clay nanotubes, which are blended with a specific polymer base employing NaturalNano’s patent pending technology. The resulting product is a drop-in additive. Pleximer does not require the expensive exfoliation process required by platy clay systems. It successfully provides the needed dispersion in a polymer matrix.  

The Company’s short-term goal is to make commercial quantities of high-quality naturally occurring nanotubes - along with licenses based on NaturalNano’s proprietary technologies - available for an extensive assortment of uses. 

NaturalNano’s team of scientists and researchers are developing methods of separating out the nanotubes and processing them for use in a number of commercial applications. These include additives in polymers and plastics, electronic components, cosmetics, as well as home and personal care products.

NaturalNano, Inc. (NNAN), closed Friday's trading session at $0.0018, up 50.00%, on 29,675,942 volume with 72 trades. The average volume for the last 60 days is 4,318,980 and the stock's 52-week low/high is $0.0001/$0.0048.

FastFunds Financial Corp. (FFFC)

PennyStocks24, Top Stock Tips, PSNO.ORG, Wallstreetlivechat, and Purely Penny Stocks reported earlier on FastFunds Financial Corp. (FFFC), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in West Palm Beach, Florida, FastFunds Financial Corp. is a holding company that lists on the OTCQB. The Company presently operates in the financial services industry division with a single credit card services portfolio. FastFunds Financial, in concert with their subsidiary, NET LIFE, has developed a unique new mortgage product that is not based on credit history (no doc) or personal guarantees. The Company’s objective is also to look for other business opportunities in natural resources and consumer products to expand their reach and diversify their business segments.

NET LIFE'S two financial instruments are NET LIFE LCMO (Life Collateralized Mortgage Obligation) and NET LIFE LCDO (Life Collateralized Debt Obligation). A NET LIFE LCMO is a residential, business or corporate real estate mortgage. All NET LIFE LCMO mortgages are processed, managed, and serviced precisely like a conventional mortgage without all of the red-tape qualification.
The underlying collateral and a life insurance policy on the borrower only secure the new mortgage product. Accordingly, all that is required to qualify for a mortgage loan is qualifying for a life insurance policy, a down payment that usually amounts to 10 percent of the purchase price, and verification that the borrower has the financial ability to pay the monthly payments.

FastFunds Financial and their wholly owned subsidiary NET LIFE Processing, Inc. announced earlier in 2013 that they reached an agreement with NET LIFE Financial Holdings regarding the compensation for processing the NET LIFE mortgages. FastFunds will receive compensation gross 1 percent of the loan value of each mortgage closing. NET LIFE Financial has an average mortgage amount of $150,000 per application. NET LIFE Financial Processing, Inc. is a development stage company formed in 2013. They earlier acquired the assets related to the processing and servicing of loans generated from NET LIFE Financial Holdings Trust.

Today, FastFunds Financial provided an update on their majority owned subsidiary, Financiera Moderna (FM). FM previously announced (October 10, 2013) the signing of a term sheet that would provide FM the capability to market their developed products to the Spanish speaking market. This transaction would also give FM/FFFC an interest in a Spanish direct sales organization and a Spanish branded real estate firm. FM/FFFC reported that definitive documents have been completed and circulated to all of the interested parties involved in the transaction for their review.

FastFunds Financial Corp. (FFFC), closed Friday's trading session at $0.0005, even for the day, on 73,093,167 volume with 98 trades. The average volume for the last 60 days is 20,801,049 and the stock's 52-week low/high is $0.0002/$0.15.

Power of the Dream Ventures, Inc. (PWRV)

Whisper from Wall Street, FeedBlitz, Otcstockexchange, AllPennyStocks, and OTCPicks reported previously on Power of the Dream Ventures, Inc. (PWRV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Power of the Dream Ventures, Inc. is one of Hungary's leading technology holding companies. The Company identifies, invests in, and acquires technologies originating in Hungary that they consider to be globally marketable. They presently hold equity interest in iGlue, Inc., a U.S. public company. By way of their wholly owned subsidiary, Genetic Immunity, Power of the Dream Ventures now concentrates on the commercialization tasks related to Genetic Immunity's lead product candidate DermaVir, a therapeutic HIV vaccine. Genetic Immunity is a biotechnology company they acquired in October 2012.

Founded in 2006, Power of the Dream Ventures has their corporate headquarters in Budapest, Hungary. The Company’s shares trade on the OTC Markets’ OTCQB. Power of the Dream Ventures is looking to generate revenue via the sale of Genetic Immunity's Therapeutic Vaccines upon U.S., European, and international marketing approvals, as well as through the sale of their equity interest in iGlue, Inc.

The Company’s Genetic Immunity subsidiary is a Phase III clinical-stage biotechnology company. Their focus is on the discovery, development, and commercialization of a new class of immunotherapeutic biologics (Immune Therapies or Therapeutic Vaccines) for the treatment of chronic viral infections, cancer, and allergy. The design of their Immune Therapies are to intensify or boost specific immune responses to modify or control these currently incurable diseases. Genetic Immunity is developing therapeutic vaccines for the Human Immunodeficiency Virus (HIV) and other infectious diseases.

On August 14, 2013, Power of the Dream Ventures reported that in the next 12 months (from that date), the Company anticipates spending approximately $2,000,000 on DermaVir's regulatory approval, commercialization, as well as general administrative expenses. They believe these funds will become available to the Company from proceeds obtained from their lawsuit against the Hungarian Development Agency (from a lawsuit initiated against the National Development Agency in Hungary for breach of contract for a previously awarded grant) and from the sale of their common stock, if necessary.

Upon regulatory approval of DermaVir, Power of the Dream Ventures anticipates making considerable equipment purchases to expand their GMP manufacturing faculty and to increase their work force to completely implement commercialization tasks.

Power of the Dream Ventures, Inc. (PWRV), closed Friday's trading session at $0.085, down 29.17%, on 68,223 volume with 15 trades. The average volume for the last 60 days is 80,899 and the stock's 52-week low/high is $0.03/$0.34.

Fresh Start Private Management, Inc. (CEYY)

PennyStocks24, SmallCapVoice, OTC Stock Review, Pumps and Dumps, First Penny Picks, OTCBB Journal, and AllPennyStocks reported this month on Fresh Start Private Management, Inc. (CEYY), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Fresh Start Private Management, Inc. is a leader in alcohol treatment and rehabilitation programs. The Company has developed a highly effective program consisting of two main components used by different alcohol addiction clinics in the United States. Fresh Start Private has a program that includes a Naltrexone implant formula developed by Dr. James Rowe and owned by Trinity Rx Solutions. Fresh Start Private's Co-Founder and President is Mr. Neil Muller. He searched out an innovative treatment due to his own personal experience of trying to help a loved one battle alcohol addiction.

Fresh Start Private Management lists on the OTC Markets’ OTCQB. Founded in 2004, the Company is based in Santa Ana, California.  Fresh Start Private offers a complete alcohol treatment program designed to treat and heal the mind and body.

Clinic reports show that the treatment program has an 85 percent success rate with individuals that complete the program. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. It delivers targeted therapeutic levels of the drug Naltrexone into the body. Naltrexone is an opiate antagonist that substantially reduces physical cravings for alcohol.

The second component of the program developed by the Company is a one on one coaching program specifically tailored for the treatment of alcoholism. The design of the Life Coaching program is to address adjusting to a life without alcohol and the path of getting to a successfully rehabilitated state.

Yesterday, Fresh Start Private Management announced that they entered into a Letter Of Intent (LOI) to sell the exclusive license and distribution rights of their alcohol treatment program to JPL, LLC. Under the terms of the pending agreement, JPL will agree to pay Fresh Start Private Management an upfront licensing fee and running royalties on all program sales in the State of Connecticut. This pending agreement would create an entirely new revenue stream for Fresh Start Private.

Fresh Start Private Management, Inc. (CEYY), closed Friday's trading session at $0.144, up 46.97%, on 1,677,618 volume with 179 trades. The average volume for the last 60 days is 149,509 and the stock's 52-week low/high is $0.002/$0.098.

Sunergy, Inc. (SNEY)

StockEgg, PennyInvest, HotStockCafe, and FeedBlitz reported previously on Sunergy, Inc. (SNEY), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Sunergy, Inc. is a junior mining exploration and development Company that lists on the OTCQB. The Company controls the Nyinahin mining concession with a full prospecting license in Ghana, West Africa. In addition, Sunergy is in the renewal process for their Pampana River Rare Earth, Gold and Diamond concession in Sierra Leone, West Africa. The Company is production and acquisitions oriented; they are considering a number of additional projects suitable for near term production. Sunergy has their headquarters in Scottsdale, Arizona.

The Company is always receptive to Joint Venture participation on all of their projects. Sunergy is advancing operations in West Africa to the installation of a commercial pilot plant to separate the gold and selected other valuable minerals for sale. Recently, Sunergy formed a partnership with landowners in Liberia to develop a significant gold, diamond, and black sands project. They formed a partnership in affordable housing and building projects suitable for development in Africa.

This week, Sunergy announced that the famous Dredgemaster from Sierra Leone and the United Kingdom has joined the Sunergy Management Team as Director of Alluvial Mining in Sierra Leone and Liberia with a commitment to early profitability. Dredge has more than 40 years' experience in the Mechanical Handling and Mining Industry, mostly in Africa.

In addition, he is a master dredge operator. He will oversee the design build of another dozen or so dredges designed chiefly for Diamond and Gold recovery, but able to recover Black Sands (Ree's) and river sand.

Mr. Garrett Hale, President and Chief Executive Officer of Sunergy, stated, "I am really pleased to have Dredgemaster on our management team. As part of our ongoing commitment to upgrade management, Dredge offers us the opportunity to grow and expand our base of alluvial mining operations in both Sierra Leone and Liberia. He plans to get a half dozen dredges operating in each country this dry mining season.”

Sunergy, Inc. (SNEY), closed Friday's trading session at $0.0014, up 16.67%, on 2,784,025 volume with 29 trades. The average volume for the last 60 days is 2,660,697 and the stock's 52-week low/high is $0.0001/$0.0029.

Pharmagen, Inc. (PHRX)

Stocks Gone Wild, Investors Online Bell, and StocksFor2010.com reported earlier on Pharmagen, Inc. (PHRX), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in Silver Spring, Maryland, Pharmagen, Inc. consists of wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc. (Labs), Pharmagen Distribution, LLC, and Pharmagen Nutraceuticals, Inc.  Pharmagen is the leader in advanced solutions to the nation’s sterile pharmaceutical shortage crisis. Listed on the OTC Bulletin Board, the Company formerly went by the name Sunpeaks Ventures, Inc. They changed their corporate name to Pharmagen, Inc. in January 2013.

The Company’s long term goal is to become a Food and Drug Administration (FDA) approved manufacturer of habitually short supply, sterile pharmaceuticals. Their goal is to be the gold standard of sterile production in the United States, through a pioneering, cGMP + ® process, employing single-use, modular systems.
Pharmagen Laboratories’ (Labs) specialties include urology, pain management, hormone replacement, ophthalmology, respiratory diseases, mental and psychological disorders, and oncology. Labs’ specialities also include gynecology, muscular and skeletal locomotion (MS), trauma and burn units, neo-natal compounding, hypoallergenic compounding, and veterinary compounding.

Pharmagen Distribution is a national specialty pharmaceutical distribution company. They serve multi-specialty clinics, surgery centers, and physicians. Their products include full-line brand pharmaceuticals, injectables, vaccines, as well as a generics portfolio. Pharmagen offers a comprehensive line of products such as plasma derivatives, oncology, women’s health, vaccines, surgical, and orthopedic.

Pharmagen Nutraceuticals manufactures and distributes Over-the-Counter (OTC) branded health supplements. Their first OTC product, Clotamin™, is available countrywide. Clotamin is a multivitamin; it is specifically formulated for patients with blood clotting disorders who take blood thinners such as warfarin (Coumadin). At present, the Company is analyzing a number of OTC products that would allow them to become a strong player in the multi-billion-dollar health supplement marketplace.

This week, Pharmagen announced that they completed the registration of Pharmagen Laboratories with the Food and Drug Administration (FDA). Pharmagen recognizes the need for the FDA's oversight of the sterile compounding industry, since the tragic fungal meningitis outbreak associated with New England Compounding Center (NECC) in late 2012. In an effort to embrace the pending changes in compounding pharmacy regulation, Pharmagen's registration with the FDA moves the Company closer to full cGMP compliance; this includes adherence to Federal Statutes 21 CFR Parts 11, 210, and 211.

Pharmagen, Inc. (PHRX), closed Friday's trading session at $0.0129, up 186.67%, on 11,451,933 volume with 174 trades. The average volume for the last 60 days is 743,555 and the stock's 52-week low/high is $0.003/$0.014.


StockMister, PennyStocks24, Winning Penny Stock Picks, WePickPennyStocks, RisingPennyStocks, Super Nova Stock Picks, Super Hot Penny Stocks, Liquid Tycoon, Penny Stock Money Train, Penny Stock Pick Report, PennyPickAlerts, Penny Stock Rumble, FOX Penny Stocks, StockMister, Pumps and Dumps, AwesomeStocks, and Joe Penny Stocks reported this week on ZIM Corp. (ZIMCF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets’ OTCQB, ZIM Corp. is a provider of software products and services for the database and mobile markets. The Company’s products and services are used by enterprises in the design, development, and management of business, database, as well as mobile applications. Founded in 1996, ZIM has their corporate headquarters in Ottawa, Ontario; ZIM South America has their office in Sao Paulo, Brazil.

The foundation of the Company is their proprietary Zim Integrated Development Environment (Zim). This is a powerful development language and database system. Zim has been integral to the development and deployment of mission critical database systems for a broad spectrum of customers and industries over the past 15 years.

In addition, certain of ZIM's mobile products are provided to the consumer market. The Company’s products include Zim 8.21. This is the newest product from ZIM. Zim 8.21, using their proven Entity-Relationship Architecture and "English-like" 4GL, includes new technology providing improved performance and functionality. New features of Zim 8.21 include Thin Client, Advanced Dedicated Lock Manager, Online Back Up, and higher scalability, supporting more simultaneous users while maintaining the same level of processing.

The Company’s Torch Migration Suite and Fuzion are strong tools to migrate a Zim database to other third-party databases. Torch Migration Suite (TMS) is a unique Windows-based tool coupled to a step-by-step methodology dedicated to migrate Zim databases to other full-fledged SQL relational databases, while keeping the Zim application in its entirety. The special design of the Fuzion tool is to simplify and speed up the management of a client server environment formed by a Zim application layer connected to one or more SQL database servers.

Their products also include Zim IDE. The ZIM 8.21 IDE is a Windows based design studio. It provides a user-friendly interface for fast and efficient development and enhancement of Zim applications. ZIM’s services include Consulting Services, Training, Mobile Application Development, and Mobile Content/Services.

ZIM Corp. (ZIMCF), closed Friday's trading session at $0.02, up 66.67%, on 1,599,060 volume with 80 trades. The average volume for the last 60 days is 201,923 and the stock's 52-week low/high is $0.0001/$0.05.

Manas Petroleum Corp. (MNAP)

UndiscoveredEquities reported earlier on Manas Petroleum Corp. (MNAP), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter

Manas Petroleum Corp. is an international oil and gas company with corporate headquarters in Baar, Switzerland. The Company is changing from a pure exploration company to an exploration and production company. Their focus is on Central Asia, particularly on the Fergana Basin that extends over Tajikistan, Kyrgyzstan, and Uzbekistan. In addition, the Company focuses on Mongolia. Manas Petroleum lists on the OTCQB.

By way of their 7.2 percent equity interest in Petromanas Energy, Inc., Manas participates in exploration projects in Albania, France, and Australia. Petromanas Energy is a Canadian public company.

In Tajikistan, Manas Petroleum owns a 90 percent Working Interest (WI) in a Production Sharing Agreement comprising the license areas Zapadnyi and Severo-Zapadnyi in the Soughd area, via their wholly-owned subsidiary DWM Petroleum AG. In Mongolia, Manas owns 74 percent WI in two Production Sharing Contracts covering Blocks XIII and XIV via their wholly-owned subsidiary DWM Petroleum AG.

This week, Manas Petroleum provided a company update. DWM Petroleum is in the process of acquiring existing oil producing assets whose present output has the potential to be restored to earlier levels (between 50 and 3,500 bopd per well) and possibly increased beyond that through the rehabilitation of these fields that are currently producing 300 bopd from depths over 100m.

Effective September 27, 2013, and subject to obtaining any regulatory approvals or consents, DWM has chosen to acquire 65 percent of the company that currently owns a majority interest in the Tajik operating company, which holds the oilfield assets for an amount equivalent to USD 10.1 million dollars. Moreover, DWM's technical field studies are continuing with over 300 wells undergoing analysis and an initial work program in development.

Furthermore, in Tajikistan, DWM is in active negotiations with several experienced exploration and production groups from Russia, China, and the European Union (EU) to farm out up to 70 percent of their current 90 percent interest in CJSC Somon Oil. They are the operating company of the two exploration blocks having the licenses for risked resources of over 400 million MMBO.

Additionally, in Mongolia, the current exploration phase of both licenses have been extended until May 20, 2015, based on a one year moratorium agreed to with the Government of Mongolia.

Manas Petroleum Corp. (MNAP), closed Friday's trading session at $0.07, up 17.25%, on 839,342 volume with 48 trades. The average volume for the last 60 days is 154,189 and the stock's 52-week low/high is $0.035/$0.12.


The QualityStocks
Company Corner


NanoTech Entertainment, Inc. (NTEK)

The QualityStocks Daily Newsletter would like to spotlight NanoTech Entertainment, Inc. (NTEK). Today, NanoTech Entertainment, Inc. closed trading at $0.145, up 7.41%, on 6,578,966 volume with 708 trades. The stock’s average daily volume over the past 60 days is 5,999,429, and its 52-week low/high is $0.0005/$0.1782.

NanoTech Entertainment, Inc. reported today on the overwhelming success of their 35mm film conversion and 4K streaming demonstrations at The American Film Market held in Santa Monica, CA November 6-13. With the technologies, media and entertainment organizations can cost-effectively upgrade their vast libraries of standard and HD content to a resolution that is four times greater than full HD and can stream their films to the growing volume of 4K UHD TV set owners.

NanoTech Entertainment, Inc. (NTEK) is a conglomerate of entertainment companies focused on leveraging technology to deliver state-of-the-art entertainment and communications products. The company’s team is comprised of senior individuals who have been in the entertainment industry for more than 20 years and have a long track record of creating successful products.

Leveraging a diverse portfolio of products and technology, NanoTech is redefining the role of developers and manufacturers in the global market. The company has a unique business model with four technology business units focusing on gaming, media & IPTV, mobile apps, and manufacturing.

NanoTech’s Gaming Labs division operates as a virtual manufacturer, developing its technology and games, and licensing them to third parties for manufacturing and distribution in order to keep its overhead extremely low and operations efficient in the new global manufacturing economy. NanoTech Media develops proprietary technology which it licenses to publishers for use in their products as well as creating and publishing unique content. NanoTech Communications develops and sells proprietary apps and technology in the mobile and consumer space. Clear Memories is the global leader in 3D ice carving and manufacturing technology.

In a recent move to advance into the commercial media space, NanoTech signed a definitive agreement to acquire MagicScreen3D, a leader in the commercial implementation of glassless 3D screen technology. The company is focused on accelerating its corporate growth through additional acquisitions, licensing agreements, partnerships, and executing current business strategies. Leveraging its team’s expertise, NanoTech is well positioned to achieve greater success. Disclaimer

NanoTech Entertainment, Inc. Company Blog

NanoTech Entertainment, Inc. News:

NanoTech Entertainment Technology Proven Successful for Streaming 4K Content at American Film Market 2013

NanoTech Entertainment & Lumaforge Partner at Createasphere ETE 2013

NanoTech Entertainment Debuts Its 4K Studios at American Film Market 2013

Pan Global Corp. (PGLO)

The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.319, up 27.60%, on 2,633,390 volume with 696 trades. The stock’s average daily volume over the past 60 days is 847,046, and its 52-week low/high is $0.20/$3.50.

Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.

The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.

Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.

Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer

Pan Global Corp. Company Blog

Pan Global Corp. News:

Pan Global Corp. Shareholder Update: Pre-Closing Requirements to Acquire Small-Hydro Project on Track

Pan Global Corp. Enters Into Definitive Agreement to Acquire 100% of 5.7MW Small-Hydro Plant in India

Pan Global Corp. Releases Chairman's Letter - "Our Commitment to Make Life Green -- Our Vision and Plans"

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.099, up 23.75%, on 10,300 volume with 4 trades. The stock’s average daily volume over the past 60 days is 32,860, and its 52-week low/high is $0.03/$0.15.

Global Payout, Inc. (GOHE) specializes in customized payment solutions for businesses and organizations worldwide. The company’s global network of banks and processing partners enable companies and organizations to efficiently deploy a customized payment solution configured specifically for each client. From solving a single payment issue to meeting an entire global payment requirement, Global Payout in conjunction with its partners delivers modular payment solutions.

Global Payout has a product line of prepaid "off the shelf" products that can be utilized or Global Payout can customize payment solutions for qualified businesses. By coupling its network of international banks and third-party processing relationships with an innovative payment platform, Global Payout enables organizations to "plug into" an efficient and cost effective method of paying employees, contractors, investors, and commissioned agents wherever they might be located in the world.

Global Payout began operations as a business to business provider of pre-paid debit cards for payroll and general spend programs. The company then launched a Prepaid Discover® card to meet the demand of its business clients in the United States. As a result of these efforts and with the input of their client base, Global Payout then greatly extended its reach by developing a new proprietary “payment platform” which enables companies and organizations to make necessary payments in every country a company does business. Clients can now make international payments without the need to establish banking relationships in each and every country they do business. Businesses now have an efficient, compliant and simplified system to make their all necessary international payments using Global Payout’s proprietary payment platform.

Global Payout delivers dependable and secure global payment solutions for companies worldwide. This relieves clients of burdensome and time consuming efforts to establish banking relationships everywhere they do business. The company’s “consolidated payment gateway” product can be configured specifically to the needs of each client within a short period of time. Global Payout is led by a management team comprised of pioneers in domestic and international payment delivery solutions. The company is well positioned to leverage their long standing international financial relationships to expand their services and global reach. Even during this expansion, Global Payout remains committed to serving domestic and international clients and providing them with customized one-stop solutions that address each client’s specific payment needs. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout, Inc. Announces Engagement of QualityStocks Investor Relations Services

ImageWare Systems Provides Next Generation Cloud Identity Management and Authentication Services to Global Payout's MoneyTracTM Consolidated Payment Gateway

Global Payout Announces Significant Increase In Revenue for Third Quarter 2013; New CEO Interview Now Available

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.152, up 4.11%, on 194,815 volume with 39 trades. The stock’s average daily volume over the past 60 days is 662,050, and its 52-week low/high is $0.13/$0.41.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation to Present Data From Its Parkinson's Disease Program at Society for Neuroscience Annual Meeting

International Stem Cell Corporation to Host Third Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Wednesday, November 13, 2013

International Stem Cell Corporation Announces New Data From Parkinson's Disease Program

Calpian, Inc. (CLPI)

The QualityStocks Daily Newsletter would like to spotlight Calpian, Inc. (CLPI). Today, Calpian, Inc. closed trading at $1.30, up 8.33%, on 9,000 volume with 7 trades. The stock’s average daily volume over the past 60 days is 7,527, and its 52-week low/high is $0.88/$2.65.

Calpian, Inc. (CLPI) has forged a powerful combination of steady cash flow here in the U.S. on the one hand, and explosive growth potential abroad in India on the other. Both business units are growing fast and creating huge value that has so far gone largely overlooked due to the company’s rapid rise.

Calpian is a leader in the U.S. business for providing access to credit and debit card payment processors for merchants and also for making investments in the resulting cash flow streams. Calpian's management team, with over 60 years of combined experience in payments, has also tapped into a super-hot growth opportunity in India where it is the leader in consumer payments using the cell phone - the most powerful financial trend in the developing world today. The company's revenues in India grew 300% year to year and are headed for triple digit growth again in 2013. Examples of this service in other countries like Kenya show that consumers need this simple payment tool and adopt it quickly. In Kenya, over 90% of the adult population has adopted a mobile phone money transfer system known as M-PESA, which produces over $100 million pretax profit after only 7 years in business. Calpian is providing this same service in India via Money on Mobile (MoM). India is a market at least 30 times larger than Kenya with vast potential. Calpian is the undisputed market leader in the space and looks poised to dominate the largest market for this service in the world with almost 1 billion cell phones.

In the U.S., the company has carved out a solid niche in the growing $1B plus annual residuals space for credit card usage by providing a silver bullet solution including their own gateway that merchants use to connect with large payment processors. Calpian is providing its merchant services through its wholly owned subsidiary, Calpian Commerce continues to sign merchants to card processing contracts, while Calpian itself continues acquiring additional recurring monthly cash flows from the over 10,000 smaller Independent Sales Organizations (dealers) throughout the U.S. The management team has been together for decades refining this business model through over 200 acquisitions in their careers before making it public in 2010. The team is experienced and well known throughout the industry as the go-to guys for making a deal.

In India, with Calpian acquiring an interest in March 2012 in Digital Payments Processing Limited (DPPL), which delivers the payment processing service for the Money on Mobile solution, it has taken off with incredible force, signing an incredible 53 million consumers though its vast network of 143,000 retailers (and growing at least 3,000 per month) so far. This astonishing growth is thanks in large part to how elegantly the company's mobile payment application, which is already seen as the “PayPal” of India, satisfies all the needs of the average Indian consumer, distributor, and retailer alike. The vast swathes of under-banked and unbanked consumers in India represent the tip of a much larger global iceberg for this solution as well, a solution whose backbone is simple SMS text protocol, and which bundles all the right incentives together for emerging markets. MoM is the runaway leader at this time in India pacing at 20 times larger than its nearest competitor. Disclaimer

Calpian, Inc. Company Blog

Calpian, Inc. News:

Calpian Inc. Subsidiary Money-on-Mobile Honored with Two Prestigious Awards

Calpian Inc. CEO Harold Montgomery to Present at the Sixth Annual LD Micro Cap Conference in Los Angeles on December 5, 2013

Calpian Inc. Subsidiary Money-on-Mobile Receives Five Year Renewal of Authorization from the Reserve Bank of India to Continue Mobile Payments System

Max Sound Corp. (MAXD)

The QualityStocks Daily Newsletter would like to spotlight Max Sound Corp. (MAXD). Today, Max Sound Corp. closed trading at $0.21, off by 1.87%, on 231,253 volume with 42 trades. The stock’s average daily volume over the past 60 days is 261,888, and its 52-week low/high is $0.165/$0.50.

Max Sound Corp. (MAXD) is an HD Audio Technology company with proprietary software that significantly improves the sound quality from virtually any digital or analog source - without increasing file size. Leveraging a strategic software licensing business model, MAX-D’s market is vast and includes improving recorded music, movies, audio books, live streaming, televised events, video games, television network programming, and all audio on mobile devices.

Through Max Sound’s recent acquisition of Liquid Spins, MAX-D has aligned its Technology with a significant audience who purchase music through smart devices. Liquid Spins is a digital media distribution company that has contracts with all major record labels in the United States, and specializes in targeted marketing strategies that focus on selling music in areas where music is not currently sold.

Backed by seasoned management, a competitive advantage, and strong intellectual properties, the company’s MAX-D Audio Process is poised to revolutionize the way consumers listen to media and communicate on their mobile devices. The MAX-D Technology restores audio to the highest quality in real time, while maximizing the output potential of virtually any device - without requiring any equipment change or upgrade in infrastructure.

Consumers have become unaware that they are listening to inferior compressed audio – in much the same way that HD television opened our eyes to a better picture quality, MAX-D opens our ears, to a realistic, true to life listening experience. MAX-D™ is Audio Perfected. Disclaimer

Max Sound Corp. Company Blog

Max Sound Corp. News:

MAX-D® HD Delivers Audio Perfection Experience on Snapdragon® DSP

Max Sound Corporation to Present at Singular's 8th Annual Best of the Uncovereds Conference

Max Sound Corporation CEO Featured in Equities.com Interview

Raptor Resources Holdings Inc. (RRHI)

The QualityStocks Daily Newsletter would like to spotlight Raptor Resources Holdings Inc. (RRHI). Today, Raptor Resources Holdings Inc. closed trading at $0.013, even for the day, on 62,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 74,022, and its 52-week low/high is $0.0018/$0.0395.

Raptor Resources Holdings Inc. (RRHI) is a publicly traded holdings company focused on mineral resource acquisition, exploration, and development. The company currently has two subsidiaries: Mabwe Minerals Inc. (MBMI), a natural resources and hard asset company engaged in the mining and commercial sales of industrial minerals & metals with first focus on barite; and TAG Minerals Inc., a mineral & metal resource acquisition, exploration, and development company with first focus on alluvial surface gold.

Mabwe Minerals has been the focus of the parent company’s efforts the last two years to move into commercial barite production. RRHI shareholders share a common interest with MBMI shareholders in the success of Dodge Mine as the parent company owns 90M shares of MBMI. The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc.

TAG Minerals, along with its indigenous affiliate, TAG Minerals Zimbabwe (Private) Limited, is responsible for alluvial gold production along with the development of greenfield assets targeting bedrock gold and other potential metals & minerals. As MBMI is transitioning into commercial barite production, RRHI will now focus on building assets within TAG Minerals with the intent of moving into commercial production within the next 18 months. TAG Minerals will utilize the latest in Heavy Particle Concentrators (HPC-30/HPC-100) through its relationship with Extrac-TEC whose gold recovery and mineral separation technology captures up to 98% of alluvial gold down to 50 microns. The company is in early stage exploration evaluating potential alluvial sites to ensure they meet the company's criteria for commercial production. Coupled with MBMI's acquisition of WGB Kinsey & Company, TAG Minerals is well positioned to fast track into commercial production once the company has successfully completed its exploratory testing.

RRHI management continues to improve its balance sheet as reflected in the company's SEC 10k filing, including favorable reductions in the company's debt/liabilities and securing 54.4M shares and 14.4M warrants of RRHI from prior employees. The company is committed to growing its asset base in TAG Minerals moving forward. Disclaimer

Raptor Resources Holdings Inc. Company Blog

Raptor Resources Holdings Inc. News:

Mabwe Minerals Launches New Web Site as Affiliate Finalizes Barite Specification Sheets to Commence Barite Qualification

Mabwe Minerals Commences Mining Operations at Dodge Mine

Mabwe Minerals Completes Strategic Alliances With Steinbock Minerals Ltd. and Yasheya Ltd.

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.3134, even for the day. The stock’s average daily volume over the past 60 days is 3,537, and its 52-week low/high is $0.25/$0.90.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Provides Update on $36 Million Strategic Financing Agreement

VistaGen Therapeutics Presents CardioSafe 3D and LiverSafe 3D Developments at International Society of Stem Cell Research's 11th Annual Meeting

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251